ArticleBMC biology2025
Prediction of human pathogenic start loss variants based on self-supervised contrastive learning.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of human pathogenic start loss variants based on self-supervised contrastive learning.BMC biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundStart loss variants are a class of genetic variants that affect the bases of the start codon, disrupting the normal translation initiation process and leading to protein deletions or the production of different proteins. Accurate assessment of the pathogenicity of these variants is crucial for deciphering disease mechanisms and integrating genomics into clinical practice. However, among the tens of thousands of start loss variants in the human genome, only about 1% have been classified as pathogenic or benign. Computational methods that rely solely on small amounts of labeled data often lack sufficient generalization capabilities, restricting their effectiveness in predicting the impact of start loss variants.
resultsHere, we introduce StartCLR, a novel prediction method specifically designed for identifying pathogenic start loss variants. StartCLR captures variant context information from different dimensions by integrating embedding features from diverse DNA language models. Moreover, it employs self-supervised pre-training combined with supervised fine-tuning, enabling the effective utilization of both a large amount of unlabeled data and a small amount of labeled data to enhance prediction accuracy. Our experimental results show that StartCLR exhibits strong generalization and superior prediction performance across different test sets. Notably, when trained exclusively on high-confidence labeled data, StartCLR retains or even improves the prediction accuracy despite the reduced amount of labeled data.
conclusionsCollectively, these findings highlight the potential of integrating self-supervised contrastive learning with unlabeled data to mitigate the challenge posed by the scarcity of labeled start loss variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.